Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II open-label dose optimization clinical trial of Zalypsis (PM00104) in patients with relapsed/refractory multiple myeloma [Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis (PM00104) en pacientes con mieloma múltiple recaído/refractario]

Trial Profile

Phase II open-label dose optimization clinical trial of Zalypsis (PM00104) in patients with relapsed/refractory multiple myeloma [Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis (PM00104) en pacientes con mieloma múltiple recaído/refractario]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; PM 00104 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors PharmaMar

Most Recent Events

  • 12 Apr 2022 Status changed from recruiting to completed, according to European Clinical Trials Database.
  • 21 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top